

Impact of Approved Drug Labeling on Chronic Opioid Therapy: RADARS[®] System Findings

Jody L. Green, PhD, CCRP

*Director of Research Administration,
Rocky Mountain Poison and Drug Center*

*Assistant Professor, School of Nursing (Research),
Vanderbilt University Medical Center*

07 February 2013



Disclosure

- RADARS® System is independently owned and operated by Denver Health & Hospital Authority, a political subdivision of the state of Colorado.
- Funding for the RADARS System comes from data subscriptions, including many manufacturers of opioids.
- Subscribers do not have any RADARS System program decision-making authority.

RADARS® System

- RADARS System monitors prescription drug abuse and diversion nationally from multiple perspectives:
 - 53 Participating Regional Poison Centers
 - 73 Opioid Treatment Programs (public & private) from 33 states
 - 280 Drug Diversion Units (nationally)
 - 6000 College Students annually (nationally)
 - Street price from crowdsourcing website (www.StreetRx.com)


Key Points

- Not all LA/ER opioids have high abuse, in some cases immediate-release opioids are just as highly abused as the LA/ER opioids.
- Abuse deterrent formulations reduce the abuse and diversion of a product.
- Access to prescription analgesics for legitimate pain patients must be maintained.

RADARS[®] System Poison Center Program

Intentional Exposures per 1,000 URDD

1Q2007 - 2Q2012




ER Oxycodone

Abuse Resistant Formulation Launch end of 2010

Poison Center Intentional Abuse Rate

Before and after reformulation [1Q 2008 to 3Q 2012]

	% Change	p-value
ER oxycodone	-40.45%	p < .0001
Other Opioids	5.30%	p = 0.111




ER Oxycodone

Abuse Resistant Formulation Launch end of 2010

Drug Diversion Rate

Before and after reformulation [1Q 2008 to 3Q 2012]


	% Change	p-value
ER oxycodone	-49.51%	p < .0001
Other Opioids	0.58%	p = 0.959



ER Oxymorphone

Abuse Resistant Formulation Launch early 2012
Poison Center Intentional Abuse Rate
 before and after reformulation [1Q 2008 to 3Q 2012]

	% Change	p-value
ER oxymorphone	-62.77%	p < .0001
Other Opioids	-5.80%	p = 0.053



Summary

- IR products and non-abuse deterrent products have high rates of abuse.
- Introduction of abuse deterrent products results in decreased abuse of that product.
- Limiting prescriptions is reasonable as long as it doesn't prevent legitimate pain patients from receiving appropriate treatment.

Thank You

www.RADARS.org